Biological and methodological features of the measurement of S100B, a putative marker of brain injury

Gonçalves, Carlos‐Alberto; Leite, Marina Concli; Nardin, Patrícia

doi:10.1016/j.clinbiochem.2008.04.003

Cited by 225 publications

(176 citation statements)

References 107 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…It has the unique property to appear both as homo-or hetero-dimers (18,19). The homodimer S100B-B is the subtype released mainly by the brain, thus it may be more specific than the total S100B levels (which was measured in our study) in predicting BBB disruption and brain metastases in lung cancer (8).…”

Section: Discussionmentioning

confidence: 93%

S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer

Choi

Puvenna

Brennan

et al. 2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Background: S100B is an astrocytic protein that enters the blood stream when there is disruption of the blood-brain barrier (BBB). Over time, antibodies against S100B develop in the sera of patients who experience persistent or repeated BBB disruptions. We explored the use of serum S100B protein and S100B autoantibodies for the detection of brain metastasis in patients with lung cancer.Methods: One hundred and twenty eight untreated patients with lung cancer who had brain imaging performed as part of their routine evaluation, participated. Serum S100B protein levels were measured by direct ELISA and S100B autoantibody levels by reverse ELISA. These levels in patients with brain metastases were compared alone and in combination to those without brain metastases.Results: Eighteen (14%) patients had brain metastasis at the time of lung cancer diagnosis. An S100B cutoff of 0.058 ng/mL had a sensitivity of 89% and specificity of 43% for brain metastasis. When an autoantibody threshold of <2.00 absorbance units was used in conjunction with S100B, the sensitivity remained at 89%, and the specificity increased to 58%. The overall accuracy was 51% with S100B alone, improving to 62.5% when combined with autoantibodies.Conclusions: Serum S100B and S100B autoantibody levels may help to identify which lung cancer patients have brain metastases.

show abstract

Section: Discussionmentioning

confidence: 93%

S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer

Choi

Puvenna

Brennan

et al. 2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…S100β is a calcium-binding protein primarily expressed and secreted by astrocyte cells in the central nervous system; acute elevation of extracellular S100β has been observed in injury conditions (20). NSE and S100β expression levels have been considered markers of neurodegeneration and are thought to be associated with the severity of the disease (21,22).…”

Section: Discussionmentioning

confidence: 99%

Paeoniflorin attenuates hippocampal damage in a rat model of vascular dementia

Zhang¹,

Wang

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Paeoniflorn (PF), the principal bioactive component of Paeoniae radix prescribed in traditional Chinese medicine, possesses a wide range of biological effects and exhibits neuroprotective effects in numerous diseases. Previous studies have demonstrated that PF significantly attenuates memory impairment in rats with vascular dementia (VD). In the present study, a bilateral common carotid artery occlusion (BCCAO) rat model was used to explore the underlying mechanisms of PF. The expression levels of neuron-specific enolase (NSE), S100β, B-cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein, cytochrome c and brain-derived neurotrophic factor (BDNF) in the hippocampus were measured by western blot analysis. The results showed that administration of PF for 28 days significantly decreased the expression levels of NSE and S100β, both sensitive markers for brain damage, in vascular dementia (VD) model rats. In addition, PF inhibited the initiation of apoptotic cell death and attenuated the decreased expression levels of BDNF induced by bilateral common carotid artery occlusion. These data confirm the neuroprotective effects of PF on VD and provide a novel insight into the long-term use of PF as a potential treatment in the stages of early cognitive impairment in VD.

show abstract

“…Intracellularly, this protein is involved in in the regulation of a large variety of cell activities and in the regulation of cell morphology (Goncalves et al, 2008, Kleindienst & Bullock 2006. S100B is also released into the extracellular space where seems to have both toxic/degenerative and trophic/reparative roles depending on the concentration (Goncalves et al, 2008).…”

Section: S100bmentioning

confidence: 99%

Novel Strategies for Discovery, Validation and FDA Approval of Biomarkers for Acute and Chronic Brain Injury

Mondello¹,

Kobeissy²,

Jeromin³

et al. 2012

Brain Injury - Pathogenesis, Monitoring, Recovery and Management

View full text Add to dashboard Cite

Biological and methodological features of the measurement of S100B, a putative marker of brain injury

Cited by 225 publications

References 107 publications

S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer

S100B and S100B autoantibody as biomarkers for early detection of brain metastases in lung cancer

Paeoniflorin attenuates hippocampal damage in a rat model of vascular dementia

Novel Strategies for Discovery, Validation and FDA Approval of Biomarkers for Acute and Chronic Brain Injury

Contact Info

Product

Resources

About